



PATENT

Case Docket No. GENENT.33CP2C2

Date: January 23, 2001

04CO
01/08


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Presta, et al
Appl. No. : 09/724,524
Filed : November 27, 2000
For : HUMAN TRK RECEPTORS
AND NEUROTROPHIC
FACTOR INHIBITORS
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in
an envelope addressed to: Assistant Commissioner
for Patents, Washington, D.C. 20231, on

January 23, 2001

(Date)


Ginger R. Dreger, Reg. No. 33,055


TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231
ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with thirty-four (34) references which are not enclosed as they were previously submitted with application No. 08/359,705 filed on December 20, 1994.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment, to Account No. 11-1410. A duplicate copy of this sheet is enclosed.
- (X) Return prepaid postcard.


Ginger R. Dreger
Registration No. 33,055
Attorney of Record

GENENT.33CP2C2



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Presta, et al.) Group Art Unit Unknown
App. No. : 09/724,524)
Filed : November 27, 2000)
For : HUMAN TRK RECEPTORS)
AND NEUROTROPHIC)
FACTOR INHIBITORS)
Examiner : Unknown

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing references are not enclosed as they were previously submitted with application No. 08/359,705 filed on December 20, 1994. This Information Disclosure Statement is being filed within three months of the filing date of this application, and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 23, 2001

By: Ginger R. Dreger
Ginger R. Dreger
Registration No. 33,055
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Any Docket No.

GENENT:33CP2C2

Serial No.

09/724,524

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Presta et al.

Filing Date

Nov. 27, 2000

Group

Unknown

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
1	EP 455,460	06.11.91	EPO	C12N	15/12		
2	EP 522,530	13.01.93	EPO	C12N	15/12		

OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)

3	Barde et al., "Purification of a new neurotrophic factor from mammalian brain" <u>EMBO Journal</u> 1(5):549-553 (1982)
4	Berkmeier et al., "Neurotrophin-5: A Novel Neurotrophic Factor That Activates trk and trkB" <u>Neuron</u> 7:857-866 (November 1991)
5	Davies et al., "p75-Deficient Trigeminal Sensory Neurons Have an Altered Response to NGF but Not to Other Neurotrophins" <u>Neuron</u> 11:565-574 (October 1993)
6	Ernfors et al., "Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: Developmental and topographical expression in the brain" <u>Proc. Natl. Acad. Sci. USA</u> 87:5454-5458 (July 1990)
7	Hallbook et al., "Evolutionary Studies of the Nerve Growth Factor Family Reveal a Novel Member Abundantly Expressed in Xenopus Ovary" <u>Neuron</u> 6:845-858 (May 1991)
8	Herrmann et al., "Mediation of NGF-stimulated Extracellular Matrix Invasion by the Human Melanoma Low-affinity p75 Neurotrophin Receptor: Melanoma p75 Functions Independently of trkA" <u>Mol. Biol. Cell</u> 4:1205-1216 (November 1993)
9	Hohn et al., "Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family" <u>Nature</u> 344:339-341 (March 22, 1990)
10	Ibanez et al., "Disruption of the Low Affinity Receptor-Binding Site in NGF Allows Neuronal Survival and Differentiation by Binding to the trk Gene Product" <u>Cell</u> 69:329-341 (April 17, 1992)
11	Ip et al., "Mammalian neurotrophin-4: Structure, chromosomal localization, tissue distribution, and receptor specificity" <u>Proc. Natl. Acad. Sci. USA</u> 89:3060-3064 (April 1992)
12	Jones et al., "Molecular cloning of a human gene that is a member of the nerve growth factor family" <u>Proc. Natl. Acad. Sci. USA</u> 87:8060-8064 (1990)
13	Kaisho et al., "Cloning and expression of a cDNA encoding a novel human neurotrophic factor" <u>FEBS Letters</u> 266(1,2):187-191 (June 1990)
14	Klein et al., "The trkB Tyrosine Protein Kinase Is a Receptor for Brain-Derived Neurotrophic Factor and Neurotrophin-3" <u>Cell</u> 66:395-403 (July 26, 1991)
15	Klein et al., "trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development" <u>EMBO Journal</u> 8(12):3701-3709 (1989) ✓
16	Lamballe et al., "trkC, a New Member of the trk Family of Tyrosine Protein Kinases, Is a Receptor for Neurotrophin-3" <u>Cell</u> 66:967-979 (September 6, 1991)
17	Leibrock et al., "Molecular cloning and expression of brain-derived neurotrophic factor" <u>Nature</u> 341:149-152 (September 14, 1989)
18	Levi-Montalcini et al., "Nerve Growth Factor" <u>Physiol. Rev.</u> 48(3):535-569 (July 1968)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Dept. of Commerce
Patent and Trademark Office

Any Docket No.
GENENT. 33CP2C2

Serial No.
09/724,524

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicanti
Presta et al.

Filing Date
Nov. 27, 2000

Group
Unknown

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|----|--|
| 19 | Maisonpierre et al., "Neurotrophin-3: A Neurotrophic Factor Related to NGF and BDNF" <u>Science</u> 247:1445-1451 (March 23, 1990) |
| 20 | Meakin et al., "The nerve growth factor family of receptors" <u>TINS</u> 15(9):323-331 (1992) |
| 21 | Middlemas et al., "trkB, a Neural Receptor Protein-Tyrosine Kinase: Evidence for a Full-Length and Two Truncated Receptors" <u>Molecular & Cellular Biology</u> 11(1):143-153 (January 1991) |
| 22 | Rabizadeh et al., "Induction of Apoptosis by the Low-Affinity NGF Receptor" <u>Science</u> 261:345-348 (July 16, 1993) |
| 23 | Rodriguez-Tabar et al., "Binding of neurotrophin-3 to its neuronal receptors and interactions with nerve growth factor and brain-derived neurotrophic factor" <u>EMBO Journal</u> 11(3):917-922 (1992) |
| 24 | Rosenthal et al., "Primary Structure and Biological Activity of a Novel Human Neurotrophic Factor" <u>Neuron</u> 4:767-773 (May 1990) |
| 25 | Squinto et al., "trkB Encodes a Functional Receptor for Brain-Derived Neurotrophic Factor and Neurotrophin-3 but Not Nerve Growth Factor" <u>Cell</u> 65:885-893 (May 31, 1991) |
| 26 | Thoenen et al., "The Physiological Function of Nerve Growth Factor in the Central Nervous System: Comparison With the Periphery" <u>Rev. Physiol. Biochem. Pharmacol.</u> 109:146-178 (1987) |

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. Dept. of Commerce
Patent and Trademark Office

Any Docket No
GENENT.33CP2C2

Serial No.
09/724,524

Applicant
Presta et al.

Filing Date
Nov. 27, 2000

Group
Unknown

OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.